US panel rejects anemia drug limit in non-dialysis
GAITHERSBURG, Maryland, Sept 11 (Reuters) - Advisers to U.S. health regulators voted on Tuesday to reject a target hemoglobin level for kidney-disease patients not on dialysis, the second vote that favors drugmakers Amgen and Johnson and Johnson, which had urged a more liberal approach to treatment.
The Food and Drug Administration advisers voted against setting a limit for targeted hemoglobin of 11 grams per deciliter for Amgen's (AMGN.O: Quote, Profile, Research, Stock Buzz) Aranesp and Epogen and Johnson & Johnson's (JNJ.N: Quote, Profile, Research, Stock Buzz) Procrit, for patients with chronic kidney failure who are not on dialysis.
Earlier, the panel voted against a strict target of about 11 for kidney disease patients on dialysis, the process of clearing waste from the blood in these patients.
The meeting comes amid concerns that high doses of the drugs lead to increased risk of heart problems and even death.
The FDA usually takes the advice of its expert panels. (Reporting by Kim Dixon)
© Thomson Reuters 2008 All rights reserved
Help us advance this story. Provide relevant links or share your insights using our comment box. Please be considerate and help us by reporting any abuse you find. Reuters will delete comments that don't meet community standards.
Have a correction to this article? Email the editors
Sphere
Famine fears
Obama visits Jewish shrine